On Nov. 17th, 2015, Scott Jordan participated on a panel discussion, “Access to Capital Markets,” at the 4th Oncology Partnering & Deal Making conference in San Francisco. The presentation highlights capital flows in the biotech sector and an overview of “Direct” Investing (Limited Partners co-investing alongside “Lead” investors).

Direct investing is accelerating!

5% of LPs are investing on a direct basis and is expected to grow to over 15% by 2017. As part of this co-investment movement LPs increasingly are staffing to evaluate opportunities internally guided, co-investing alongside of General Partners without incurring “2” and “20” fee structures.

To download the presentation, click here.